In 2016, millions or American consumers will have their first video consults; be prescribed their first health apps and use their smartphones as diagnostic tools for the first time. 2016 also will be the year that many Americans, faced with higher deductibles, manage medical expenses with new tools and services rolled out by their insurance companies, healthcare providers, banks and other new entrants.
This will be the year that, shift by shift, visit by visit, nurses, doctors and other clinicians learn to work in new ways, incorporating insights gleaned from data analysis into their treatment plans.
PwC’s Health Research Institute’s annual Top health industry issues report highlights the forces that are expected to have the most impact on the industry in the coming year, with a glance back at key trends from the past decade.
High-profile mergers and acquisitions will continue in 2016, with regulators taking center stage in the debate over how consolidation impacts consumers.
Reminiscent of the proverbial story of Goldilocks, the search is on for a drug pricing formula that is “just right.”
Thanks to technology and shifts in financial incentives, care will begin to move into the palms of consumers’ hands, providing care anywhere, anytime.
As security breaches become more common and costly, attention shifts to buttressing the security of medical devices.
Shouldering higher deductibles, consumers seek help managing their health spending with fresh tools and services developed by players new and old.
Employers and healthcare organizations turn their eye to behavioral healthcare as key to keeping costs down, productivity up and consumers healthy.
As payment shifts to value-based models, health systems will pursue lower-cost settings more aggressively than before while employing creative approaches to distributing care.
New database tools will allow industry players to analyze data from many sources in novel ways, finally unlocking insights embedded in the reams of information being collected about health consumers.
Biosimilars, lower-cost substitutes for branded biologic drugs, will begin in 2016 to offer some counterweight to rising drug prices, much as generic drugs did 30 year ago.
PwC’s Health Research Institute (HRI) provides new intelligence, perspectives, and analysis on trends affecting all health related industries. HRI helps executive decision makers navigate change through primary research and collaborative exchange.
We help clients solve an array of emerging complex problems facing manufacturers, service providers, and new market entrants through our experience working with a wide range of clients in healthcare, pharmaceuticals, and life sciences industries.